Background: Dermatologic conditions cause morbidity and mortality among hospitalized cancer patients. An improved understanding is critical for implementing clinical and research programs in inpatient oncodermatology.
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Patients with cancer often suffer cutaneous manifestations of internal disease and dermatologic adverse events (dAEs) from anticancer therapies, including systemic agents, radiation, surgery, and stem cell transplants, which diminish healthrelated quality of life in the outpatient setting and impact cancer treatment adherence. 1 For instance, epidermal growth factor receptor inhibitors alone have been associated with a papulopustular rash in 45%-100% of patients, xerosis and pruritus in 12%-16% of patients, and nail changes in up to 17% of patients. 2, 3 In response, the field of supportive oncodermatology has grown to address the dynamic problems posed by patients who encounter multiple and often investigational treatment modalities. 4, 5 However, the most effective role for supportive oncodermatology in inpatient care has not been defined and is under investigation prospectively.
Inpatient consultative dermatologic services play an important and challenging role in the diagnosis and management of dAEs that emerge in patients hospitalized for cancer treatment, complications of therapy, or palliative supportive care. 6 Despite declining dermatologist involvement in hospital consultations, 7 inpatient dermatology consultations have been shown to have a significant effect on diagnostic accuracy and the management of skin conditions in the hospital setting. [8] [9] [10] By facilitating prompt and accurate recognition and interpretation of skin conditions as well as effective dermatologic treatment in hospitalized patients, inpatient consultative dermatology services perform a vital function unmet by nonspecialty services, ultimately having a meaningful impact on hospital outcomes including length of stay (LOS) and 1-year readmission rates. 8, 11, 12 Although the epidemiology of skin disease has been studied in hospitalized medical, 8, [10] [11] [12] [13] [14] [15] [16] [17] [18] pediatric, [19] [20] [21] [22] and hematologic oncology patients, [23] [24] [25] there is limited data 26 describing dAEs and other skin conditions in hospitalized patients undergoing treatment for cancer and the role of dermatology consultations in their management. Given the potential impact of inpatient dermatology consultations on maintaining quality of life, dermatologic health, and ability to receive antineoplastic therapies, an increased understanding of demographic and diseasespecific factors would be critical toward the optimization of supportive inpatient oncodermatology clinical and research efforts. 1, 4, 11 We sought to characterize and evaluate the need for inpatient dermatology consultations at a major comprehensive cancer center by studying the spectrum of diseases encountered, the circumstances in which cancer patients were found to have cutaneous concerns necessitating consultation, and the recommendations provided by consulting dermatologists for ensuring quality of care.
METHODS

Study sample
Following approval by the institutional review board of Memorial Sloan Kettering Cancer Center (protocol , an observational retrospective chart review was conducted by extracting all inpatient dermatology consultations at Memorial Sloan Kettering Cancer Center (MSK) in the 12-month period from January 1, 2015, to December 31, 2015, using a query of MSK's Health Information System and consultation log maintained by the dermatology service staff. A total of 11,533 unique inpatients with a history of malignancy were admitted for $24 hours at MSK, and 412 of them received inpatient dermatology consultations. Forty-two of these patients received [1 inpatient dermatology consultation in 2015.
A total of 824 dermatology consultation records were identified, and 320 follow-up consultations were excluded, leaving 504 initial consultations for further screening. 27, 28 For the purposes of this study, prescriptions recommended by the dermatologist included pharmaceutical interventions, and nonprescription recommendations included emollients, lymphedema therapy, and wound care. Anticancer pharmaceutical treatments were categorized as cytotoxic, targeted, immunotherapy, hormonal, investigational, and combination. Cytotoxic treatments included standard, nonselective chemotherapy (eg, cytarabine, paclitaxel); targeted treatments included novel, small-molecule inhibitors of specific oncologic targets (eg, erlotinib, sorafenib); immunotherapy included monoclonal antibodies against cancerassociated molecules (eg, rituximab, nivolumab); hormonal therapy included those that exert effects on endocrine hormone-receptor positive tumors (eg, tamoxifen, anastrozole); investigational therapies included agents not yet classifiable; and combination therapy involved agents from $2 categories. The inpatient (Tables I and II ) and the consultation (Tables III and IV) characteristics were described.
Statistical analysis
Patient characteristics were compared between groups using the chi-squared test for categorical variables and the Wilcoxon rank sum test for continuous variables. Those characteristics found to be significantly associated with the likelihood of receiving a dermatology consultation (age, sex, and primary cancer diagnosis) were further analyzed in a multivariable logistic regression model to assess for independent association. All statistical analyses were performed in SAS version 9.4 (SAS Institute Inc, Cary, NC).
RESULTS
In 2015, MSK admitted 11,533 unique patients for a median stay of 5 days (interquartile range [IQR] 3-8 days, range 2-152 days). A total of 412 inpatients with a history of malignancy required a dermatology consultation; the median age (IQR) was 59.5 (46-69) years with 47% having a hematologic malignancy. In terms of demographics, patients necessitating dermatology consultations were similar to those admitted for treatment at MSK overall. However, primary cancer diagnosis was significantly associated with dermatologic consultation (P \ .0001). Compared with all other admitted patients, patients necessitating consultation more likely had a primary diagnosis of leukemia (27% vs 4%) and lymphoma (17% vs 6%). Patients with a gastrointestinal primary cancer diagnosis were least likely to receive a dermatology consultation (consulted vs not consulted, 9% vs 27%). This association remained significant in multivariable analysis controlling for age and sex (P \ .0001). Patients with hematologic malignancies were 6 times more likely to have received a dermatologic consultation compared with patients with nonhematologic malignancies (odds ratio 6.56, 95% confidence interval 5.35-8.05). In addition, patients requiring dermatology consultation had a higher death rate during admission (9% vs 2%, P \.0001) and a longer median LOS (11 days vs 5 days) compared with MSK inpatients not requiring dermatology consultation (P \.0001; Table I ). Examining the most recent admission for each patient, the median interval from admission until dermatology consultation was 3 (IQR 1-10) days (N = 412). Among patients whose reason for most recent admission included any dermatologic issues (N = 77), the median interval from admission to dermatology consultation was 1 (IQR 1-3) day.
During this period, 42 (10%) patients who received dermatology consultation were seen at multiple distinct consultations during distinct admission periods. Compared with patients receiving 1 dermatology consultation in 2015, patients with multiple dermatology consultations were more likely to have a diagnosis of leukemia (50% vs 24%) or lymphoma (29% vs 15%) (P = .001; Table II ).
There were 471 initial consultations of the 412 patients with primary cancer diagnoses (Table III) . In 294 (62%) consultations, systemic anticancer treatment was received in the 30 days before consultation. The most common systemic therapy types were cytotoxic (135/294, 46%), targeted (52/294, 18%), and combination (79/294, 27%) chemotherapy. Some members of the cohort had undergone radiation therapy (41/471, 9%) and surgery (74/471, 16%) within 30 days of consultation. Of note, 25% (118/471) of consultations were completed on patients whose reason for admission included a cutaneous concern. The services that most frequently requested inpatient dermatology consultation were Hematology/Oncology (44%), Solid Tumor Oncology (27%), and Surgery (15%).
Table IV details the final dermatologic diagnoses made by the consulting dermatologists. There were 645 diagnoses for the 471 consultations, which reflect that in many cases multiple skin conditions were identified during a single consultation. Inflammatory conditions (27%), infections (24%), and drug reactions (17%) comprised the most common diagnostic groups. Across all diagnoses, the specific conditions of herpes zoster (4%) and contact dermatitis (3%) occurred most frequently. The most common diagnostic groups of the 335 dermatologic diagnoses among patients with hematologic malignancies were inflammatory conditions (28%), infection (23%), drug reaction (13%), and neoplasm (13%). The most frequent offending agents implicated in the 111 drug reactions were of chemotherapeutic (36%) and antimicrobial (26%) classes. Of the 40 drug reactions attributed to chemotherapy, 58% (n = 23) were related to cytotoxic agents, 18% (n = 7) to immunotherapy, 13% (n = 5) to targeted agents, 7% (n = 3) to unspecified agents, and 5% (n = 2) to investigational agents.
Biopsy and culture were recommended by the dermatologist for diagnosis in 18% (84/471) and 25% (120/471) of dermatology consultations, respectively. Most patients required topical therapy alone (42%, 199/471), and the mean number of prescriptions recommended by the dermatologist 
DISCUSSION
Inflammatory (27%) and infectious (24%) skin conditions were the most common conditions found at inpatient dermatologic evaluation; in addition, 17% of the skin conditions observed in this cohort were dAE attributable to pharmacologic therapy. These findings are comparable with previous studies examining the epidemiology of inpatient dermatology consultations in noncancerespecific hospitals as well as among hematologic oncology inpatients. 9, 18, [23] [24] [25] 29 The patients hospitalized in one noncancerespecific hospital were found to have a greater relative incidence of inflammatory conditions (31% vs 27%) and less frequent incidence of drug reactions (12% vs 17%) compared with the MSK cohort. 18 Inpatients with hematologic malignancies might develop various skin conditions, including neutrophilic dermatoses, graft-versus-host disease, and morbilliform drug eruptions. 25 In our study, 47% of inpatients requiring dermatology consultation had an underlying hematologic malignancy. Similar results were previously reported, in which 52% of inpatients at a cancer center receiving dermatology consultation had a primary diagnosis of leukemia or lymphoma. 26 Although a study of hematologic oncology inpatients showed a higher number of drug reactions (38% vs 13%) and a less frequent rate of infections (15% vs 23%), 23 another study demonstrated a more similar rate of cutaneous drug reactions and infections (22%) in patients with hematologic malignances when compared to our study population. 25 Hematologic cancer patients, who often undergo intense treatment regimens, including induction chemotherapy, stem cell transplantation, and prophylactic antibiotics, are prone to skin infections and dAEs due to their immunocompromised state and exposure to high numbers of systemic therapies. 30 These results suggest that this group of patients might need dermatologic intervention to promptly diagnose skin conditions that might arise during their hospital stay.
Furthermore, this study might help identify underlying malignancies that predispose patients to specific dermatologic conditions requiring the expertise of dermatologists for diagnosis and management. The need for dermatology consultation was significantly associated with primary cancer diagnosis independent of patient age or sex, suggesting that patients with leukemia or lymphoma require dermatologist input in their management more frequently and might be at greater risk for dAEs. Patients with hematologic malignancies might benefit from a decreased threshold for dermatology consultation and close monitoring by dermatologists, potentially expediting diagnosis and improving management and outcomes. On the other hand, the relative infrequency of dermatology consultations for patients with gastrointestinal, genitourinary, and lung cancers might reflect a decreased need for dermatology involvement or decreased risk for skin disease necessitating inpatient dermatology consultation in these patients.
Hospital LOS was significantly associated with the need for dermatology consultation (P\.0001). Of all hospitalized patients at MSK in 2015, the median LOS was 6 days longer in patients who required dermatology consultation. The increased LOS in patients who required dermatology consultation might reflect their increased comorbidity burden, greater severity of dermatologic disease, or higher propensity to develop skin conditions with more medication and nosocomial exposures during the longer hospitalization duration. In addition, the presence of any admission-to-consultation interval delay might tend to elongate the estimated LOS in the cohort of patients receiving consultations. It is further possible that delayed dermatologic consultation could delay discharge, considering J AM ACAD DERMATOL VOLUME 78, NUMBER 6 that the median admission-to-consultation interval was 3 days. Recently, dermatology consultations were associated with a reduction in hospital LOS by 2.64 days among patients admitted for inflammatory skin disorders when adjusted for admission-to-consultation lag time. 11 However, our assessment of the need for dermatology consultation is not directly comparable because we focused on cancer patients admitted for both cutaneous and noncutaneous concerns and we did not evaluate how dermatologic consultation by itself affected LOS.
The majority of patients (66%) were prescribed topical therapy for their skin conditions, and 38% required systemic therapy, which might reflect that most skin conditions encountered did not have significant systemic involvement and were managed without aggressive therapies. As suggested elsewhere, 10 the extent of topical therapy might also indicate that most consultations did not require extensive follow-up because most consultations were for uncomplicated skin conditions. However, the prescription rates in our study were greater than a previous study of hospitalized patients receiving dermatology consultation (52% topical therapy, 26% systemic therapy). 31 Regardless, dermatologists managed skin conditions without the need for further laboratory testing in most patients; superficial microbial culture was the most frequent test recommended, occuring in only 25% of consultations, which parallels the rate of infections in the cohort. The present study finding that 42% of consultations recommended some form of additional diagnostic testing falls within the range reported in the reviewed literature: 6% 17 -60%. 25 Limitations of the study include its retrospective nature, reliance on electronic medical records, and single-hospital scope. We are not able to comment on the prevalence of skin disease in all hospitalized cancer patients at MSK because our focus was on only those cases in which a consultation was deemed necessary by the primary team. In addition, placement of specific dermatologic diseases into groups before analysis inevitably introduces bias. Further analysis is required to assess the relationship between specific cancer comorbidities and the risk for particular etiologies of dermatologic conditions. Future directions that were not accounted for in the present research include examining follow-up consultations and their effect on patient outcomes as well as a detailed examination of the role of biopsy and culture in consultative services. Furthermore, exploring how consultations performed by other services (eg, infectious diseases) affect dermatology consultations would improve our understanding of the interactions of various services in the care of hospitalized cancer patients.
Conclusion
The findings of this study fill a gap in our understanding of the spectrum of skin conditions that affect inpatients with a primary cancer diagnosis, reinforcing the importance of oncodermatology collaboration, research, and education to optimize the management of hospitalized cancer patients and, in particular, inpatients with hematologic cancers.
